CCL2 and Hypercholesterolemia: In summary, the present study has demonstrated that probucol and cilostazol in combination exerted inhibitory effects against the expression of the inflammatory chemokine, MCP-1, in ischemic brains with hypercholesterolemia, which allowed identification of one of the mechanisms responsible for its anti-inflammatory action.